Sign in

You're signed outSign in or to get full access.

Tyrone Miller

Chief Financial Officer at 60 DEGREES PHARMACEUTICALS
Executive

About Tyrone Miller

Tyrone Miller is Chief Financial Officer of 60 Degrees Pharmaceuticals (SXTP), age 51 as of the latest proxy, and a Certified Public Accountant with a BBA in International Business from Emory University (1996) . He joined the company in 2014, has served as Treasurer, and helped raise over $6 million in external financing while establishing multinational financial reporting and tax strategies . An employment agreement dated January 12, 2023 governs his terms; the Board increased his base salary to $215,000 for FY2025 from $204,000 in 2024 . Company filings do not disclose TSR, revenue growth, or EBITDA growth tied specifically to his tenure—no performance metrics are provided beyond generic “performance goals or certain events” language .

Past Roles

OrganizationRoleYearsStrategic Impact
60 Degrees PharmaceuticalsCFO; previously Treasurer2014–presentRaised >$6M external financing; built multinational reporting; designed tax/credit strategies; strategic finance advisory
Sachs Figurelli, LLCSenior Accountant2002–2011Corporate/individual tax returns; reengineered accounting processes; managed payroll/property filings and staff

External Roles

OrganizationRoleYearsStrategic Impact
Miller Tax & AdvisoryFounder & Principal2011–presentAdvises closely held businesses; designed accounting systems; CPA-led practice

Fixed Compensation

Metric202320242025 (Approved)
Base Salary ($)$135,632 $204,000 $215,000 (Board-approved for FY2025)

Notes:

  • “We periodically review, and may increase, base salaries in accordance with our normal annual compensation review” .

Performance Compensation

MetricWeightingTargetActualVesting/Timing
Annual Cash BonusNot disclosed Not disclosed $20,000 (2024) Paid for 2024
Stock BonusNot disclosed Not disclosed $19,525 (2024) Not disclosed

Employment agreement provides “bonuses to the extent certain events occur or if applicable performance goals are met” (metrics not specified) .

Option Awards – Grants and Terms

Grant DateShares/UnitsExercise PriceVestingExpirationStatus/Notes
Jul 12, 2023 (initial CFO grant)12,000 total over 5 yrs (pre-split) Reset to $1.00 (Nov 2023) Modified to annual vesting (first vest 12/31/2024) 12/31/2029 At 12/31/2023: 240,000 unexercisable (pre-split count) at $1.00
Jul 16, 20244,000 options $60.00 5 equal annual tranches; first vest 12/31/2024 7/16/2034 At 12/31/2024: 800 exercisable; 3,200 unearned at $60
Jan 2, 202515,000 options $6.55 5 equal annual tranches; first vest 12/31/2024 (per Board approval) 7-year term Board approved Dec 2024; fully vested 3,000 by Aug 14, 2025

The company effected a 1-for-5 reverse stock split on Feb 24, 2025; ownership tables are adjusted post-split in 2025 filings .

Outstanding Equity Awards (reference dates)

MetricDec 31, 2023Dec 31, 2024
Unexercised Options – Unexercisable (#)240,000 at $1.00; exp 12/31/2029 3,200 unearned at $60.00; exp 7/16/2034
Unexercised Options – Exercisable (#)800 at $60.00; exp 7/16/2034

2024 Grant Date Fair Values (Summary Compensation)

Component2024 Amount ($)
Option Award (2024)$41,000
Cash Bonus (2024)$20,000
Stock Bonus (2024)$19,525

Equity Ownership & Alignment

MetricMay 30, 2024 (Record Date for 2024 Proxy)Mar 27, 2025 (10-K Record Date)Aug 14, 2025 (2025 Proxy Record Date)
Beneficial Ownership – Total Shares176,928 6,074 9,074
Ownership % of Class1.45% (12,206,116 shares o/s) Less than 1% (1,472,891 shares o/s; post 1:5 split) Less than 1% (4,104,469 shares o/s)
Direct/Common Shares Held176,928 5,274 5,274
Options – Exercisable800 at $60.00 800 at $60.00; 3,000 at $6.55 (fully vested)
Pledging/HedgingNot disclosed Not disclosed Not disclosed

Notes:

  • Section 16(a) delinquency: Company notes Mr. Miller failed to file a Form 4 regarding RSUs issued on Nov 21, 2023 .
  • Directors and officers as a group own 1.69% as of Aug 14, 2025 .

Employment Terms

TermDetails
Agreement Date & RoleEmployment Agreement dated Jan 12, 2023; CFO
Term & Auto-RenewalInitial 2-year term; automatic renewals unless 90-day prior notice
Base Salary$204,000 (2024); Board-approved increase to $215,000 for FY2025
BonusesPayable if certain events occur or performance goals are met (metrics not specified)
Severance (non‑Cause / non‑Good Reason termination)Continuation of annual salary plus health insurance benefits, up to 18 months
Change-in-Control (CIC)If terminated other than Cause/Disability or resigns for Good Reason on or within 24 months post-CIC, entitled to CIC severance (multiple not disclosed)
Non‑Compete & Non‑SolicitDuring employment and for 24 months after termination
ClawbackBoard adopted executive compensation recoupment policy Nov 23, 2023 (Rule 10D‑1/Nasdaq; restatements/fraud/misconduct) ; Plan-level clawback language also in 2024 proxy

Compensation Committee & Governance Context

  • Compensation Committee membership: Paul Field (Chair), Stephen Toovey, Charles Allen; Audit Chair: Charles Allen .
  • Equity Plan (2022 Plan): permits options/RSUs/Performance Awards, non-transferable; change-in-control treatment may accelerate vesting or cash out awards; awards must be at or above FMV at grant; outside director grant limits specified .
  • Equity award governance: timing overseen by Compensation Committee/legal counsel; policies designed to avoid improper use of MNPI; no fixed grant schedule .
  • Shareholder approvals: On July 16, 2024, stockholders increased shares authorized under the 2022 Plan; Miller’s modified options became effective then .

Risk Indicators & Red Flags

  • Section 16(a) reporting deficiency: Form 4 not filed for Miller’s Nov 21, 2023 RSUs .
  • Frequent equity modifications: Board reset prior option exercise prices/vesting schedules in Nov 2023; later granted new options in 2024–2025—monitor dilution and incentives .
  • Reverse stock split: 1-for-5 effected Feb 24, 2025; impacts reported ownership metrics .

Investment Implications

  • Alignment: Miller holds common shares and has meaningful vested options across two strikes ($60 and $6.55), suggesting economic alignment; no pledging disclosed .
  • Selling pressure: Annual vesting through 2028 (800 shares/year at $60; 3,000/year at $6.55) may create periodic liquidity events; monitor Form 4s for dispositions .
  • Retention/CIC protection: 18 months salary+benefits severance and CIC severance with a 24‑month protection window and 24‑month non‑compete reduce near‑term departure risk; exact CIC multiple not disclosed (limits precision in modeling exit economics) .
  • Pay-for-performance: Cash/stock bonuses paid in 2024, but specific metrics/weights aren’t disclosed; analysis relies on plan-level clawback and governance rather than target-based disclosure—limit in assessing pay-performance rigor .
  • Governance quality: Formal clawback policy and committee oversight are positives; prior Section 16(a) delinquency warrants monitoring of reporting controls .